CDKN2A and melanoma: For example, families with melanoma who have germline mutations in CDKN2A are well known, whereas the vast majority of sporadic melanomas have mutations in the mitogen-activated protein kinase (MAPK) cascade, which is the pathway with the highest oncogenic and therapeutic relevance for this disease.